免疫性血小板减少症
入射(几何)
医学
血栓形成
血小板
重症监护医学
内科学
儿科
光学
物理
作者
Isaac Goncalves,Cameron Lewis,Brian T. Grainger,Rebecca Dring,Nora Lee,Sant‐Rayn Pasricha,Jeff Szer,Kylie D. Mason
标识
DOI:10.1016/j.rpth.2024.102342
摘要
Essentials•Patients with immune thrombocytopenia (ITP) are at increased risk of thrombosis.•Age, secondary ITP, and thrombopoietin receptor agonists confer high thrombosis risk factors.•Antithrombotic therapy is deliverable and safe in patients with ITP.•Thrombosis risk factor assessment should be evaluated throughout the patient's ITP history.AbstractBackgroundThere is evidence that patients with immune thrombocytopenia (ITP) are at increased risk of thrombosis. However, the association of clinical- and treatment-related factors with thrombosis remains controversial.ObjectivesTo evaluate the incidence and impact of risk factors for arterial and venous thromboembolism (VTE) in patients with ITP and characterize the clinical features and management of patients.MethodsWe performed a retrospective cohort study (January 1, 2011, to October 30, 2022) of adult patients diagnosed with ITP from an Australian tertiary hospital. The incidence rates of thrombosis were calculated in terms of person-years of follow-up. Multiadjusted Cox regression was used to estimate associations.ResultsA total of 220 patients with 1365 person-years of follow-up since ITP diagnosis revealed 26 (11.8%) patients with a total of 37 thrombosis events, 29 (78%) VTE and 8 (22%) arterial thromboembolism (ATE). The incidence rate of thrombosis was 2.71 (95% CI, 1.97-3.72) (0.66 [95% CI, 0.33-1.26] for arterial thromboembolism and 2.05 [95% CI, 1.42-2.95] for VTE) per 100 person-years. Mean age and median time to first thrombosis diagnosis was 56 and 2.13 years, respectively. Age, secondary ITP, lines of therapy, thrombosis risk factors, and thrombopoietin receptor agonist therapy were independently associated with thrombosis. Almost all patients (25 of 26, [96%]) had good ITP disease control prior to thrombosis diagnosis, and antithrombotic therapy was deliverable and well tolerated.ConclusionDiagnosis of thrombosis in patients with ITP, while infrequent, is of clinical significance. We identified from a heterogeneous real-world cohort that older patients with multiply-treated secondary ITP receiving thrombopoietin receptor agonists are at the highest risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI